RxDoctor Payments Data

Tamera Spangler, DO

Family Medicine · Irvine, KYNPI 1316387079

Payments from drug & device makers

$3,828in general payments, 2019–2025

Across 252 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$454
  • AbbVie$329
  • GSK$272
  • Novo Nordisk$235
  • Pfizer$227
  • Astellas Pharma US Inc$212
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$3,813100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,828 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,780
Medicare patients
103
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate52$76,025
EliquisApixaban71$75,772
MounjaroTirzepatide36$73,310
JardianceEmpagliflozin47$73,067
TrulicityDulaglutide37$65,611
ProliaDenosumab20$33,913
OzempicSemaglutide25$31,826
XareltoRivaroxaban33$31,802
MyrbetriqMirabegron33$28,372
JanumetSitagliptin Phos/Metformin Hcl12$19,749
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$19,504
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$15,865
Breo ElliptaFluticasone/Vilanterol24$15,196
LinzessLinaclotide12$11,790
VascepaIcosapent Ethyl17$11,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$454$138,92173 claims
PfizerEliquis$227$75,77271 claims
Boehringer IngelheimJardiance$184$73,06747 claims
GSKAnoro Ellipta, Breo Ellipta$272$34,70067 claims
AmgenProlia$187$33,91320 claims
Novo NordiskOzempic$235$31,82625 claims
Johnson & JohnsonXarelto$97$31,80233 claims
Astellas Pharma US IncMyrbetriq$212$28,37233 claims
AstraZenecaBreztri Aerosphere, Symbicort$200$18,97326 claims
AbbVieLinzess$329$11,79012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Irvine

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →